🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “The First People's Hospital of Lianyungang” Clear

  1. PEG-somatropin

    The First People's Hospital of Lianyungang

    Short Stature Children Born Small for Gestational Age (SGA)

    phase 2 mab active

    1 trial

  2. PLD and Carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen

    The First People's Hospital of Lianyungang

    NK-T-Cell Lymphoma, Extranodal

    phase 2 small molecule active

    1 trial

  5. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  6. Pemetrexed

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  7. Pemetrexed

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis

    phase 2 small molecule active

    2 trials

  8. Pemetrexed (1)

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastases

    phase 2 small molecule completed

    1 trial

  9. Pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  10. Plerixafor

    The First People's Hospital of Lianyungang

    Relapsed Adult ALL

    phase 2 small molecule active

    1 trial

  11. Postoperative adjuvant lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  12. Pre-operative chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Preoperative lanreotide treatment

    The First People's Hospital of Lianyungang

    Acromegaly

    phase 2 small molecule active

    1 trial

  14. Pyrotinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  15. Pyrotinib, trastuzumab, paclitaxel-albumin

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  16. QL1706

    The First People's Hospital of Lianyungang

    Local Advanced Esophageal Cancer

    phase 2 small molecule active

    1 trial

  17. QL1706 (Iparomlimab/Tuvonralimab)

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  18. QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  19. Radiation+PD-1 Ab

    The First People's Hospital of Lianyungang

    Proton Therapy

    phase 2 other active

    1 trial

  20. Radiation: Proton Therapy+PD-1 Ab

    The First People's Hospital of Lianyungang

    Proton Therapy

    phase 2 other active

    1 trial

  21. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  22. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  23. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  24. Radiotherapy plus temozolomide

    The First People's Hospital of Lianyungang

    Glioma (Any Grade) in the Brain

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources